ABBV Stock Recent News
ABBV LATEST HEADLINES
ABBV's Q2 results are likely to hinge on Skyrizi and Rinvoq growth as Humira declines, with 2025 set for a strong revenue rebound.
Let's look at five biotech and drug companies, MRK, AZN, BMY, ABBV and MRNA, slated to release their second-quarter 2025 results this week.
I like dividend stocks. You probably should, too, even if you aren't interested in the income they provide.
AbbVie (ABBV) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Key Points ETFs have generated higher returns than mutual funds. GLD, VYM, and QQQ have the potential to outpace S&P 500. Are you ahead, or behind on retirement? SmartAsset’s free tool can match you with a financial advisor in minutes to help you answer that today. Each advisor has been carefully vetted, and must act in your best interests. Don’t waste another minute; get started by clicking here.(Sponsor) 2025 hasn’t been a smooth ride. The economy has seen volatility, the market has seen several ups and downs, and investors are scrambling to look for low-risk options to invest their money. There are concerns about the impact of tariffs, and consumer spending is low. Amidst the uncertainty, the only way to invest is to look for low-volatility investment options that can generate steady income. Exchange-traded funds have emerged as one of the top investment options this year. They allow investors to own a collection of stocks with just one investment and at a low cost. I was
(OPTIMIZED VIDEO SPECIFIC DESCRIPTION)
AbbVie (ABBV) reached $187.12 at the closing of the latest trading day, reflecting a +1.23% change compared to its last close.
I maintain my Buy rating on AbbVie, emphasizing its medium-to-long-term potential despite recent outlook downgrades and tariff risks. Recent guidance cuts are minor and don't meaningfully undermine the investment case; with earnings growth expected in Q2 2025. The company's dividends add to its attractiveness at an uncertain time, adding to robust price returns over time.
ABBV's neuroscience sales are projected to jump 15% in Q2, driven by Botox Therapeutic, Vraylar and oral migraine drug gains.
14 Dividend Kings continue to outperform the S&P 500 in 2025. Dividend growth remains healthy, with one recent increase and a collective 2025 growth rate of 5.23%. Seventeen Dividend Kings currently appear undervalued with strong long-term return potential, using Dividend Yield Theory for valuation.